pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KODKodiak Sciences Inc.

$KOD43.41+3.09%
Palo Alto, CA, USupdated 6h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
tarcocimab tedromer
Retinal Vein Occlusion

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 12, 2026
earnings
$KOD43.41+3.09%
yesterday
Kodiak Sciences Inc. earnings
Kodiak Sciences Inc.
→
view all catalysts →

Active trials

  • phase3A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKactive not recruitingn=675
  • phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLErecruitingn=150
  • phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKrecruitingn=150
  • phase3A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)active not recruitingn=255
  • phase3A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)terminatedn=253
  • phase3A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)terminatedn=459
  • phase3A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)terminatedn=460
  • phase3A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.terminatedn=559
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer12,477 sh @ $40.29−$503K↗
  • Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer12,692 sh @ $39.14−$497K↗
  • Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer4,231 sh @ $40.88−$173K↗
  • Apr 2, 26SELLBORGESON JOHN A.· Chief Financial Officer600 sh @ $41.77−$25K↗
routine RSU / option mechanics (6)
  • Apr 15, 26option exerciseBORGESON JOHN A. · Chief Financial Officer28,614 sh
  • Apr 15, 26option exerciseBORGESON JOHN A. · Chief Financial Officer28,614 sh
  • Apr 2, 26option exerciseBORGESON JOHN A. · Chief Financial Officer30,000 sh
  • Apr 2, 26option exerciseBORGESON JOHN A. · Chief Financial Officer30,000 sh
  • Mar 25, 26option exercisePERLROTH VICTOR · Chairman and CEO300,000 sh
  • Mar 25, 26option exercisePERLROTH VICTOR · Chairman and CEO300,000 sh
🐶 Hiring Signal
No open roles indexed yet — view Kodiak Sciences Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$KOD
SEC CIK
0001468748
country
US
source
sec_tickers
top tags
Ophthalmology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 24m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?